APO Research
Talk to an analyst

APO RESEARCH · REPORT

Postmenopausal Vaginal Atrophy (PVA) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025186 pages

Choose your research edition.

Industry ResearchPostmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Postmenopausal Vaginal Atrophy (PVA) Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Postmenopausal Vaginal Atrophy (PVA) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Postmenopausal Vaginal Atrophy (PVA) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Postmenopausal Vaginal Atrophy (PVA) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Postmenopausal Vaginal Atrophy (PVA) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Postmenopausal Vaginal Atrophy (PVA) Therapeutics include Teva Pharmaceuticals, Pfizer, Shionogi & Co, Novo Nordisk, Endoceutics and Accord Healthcare, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Postmenopausal Vaginal Atrophy (PVA) Therapeutics market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Postmenopausal Vaginal Atrophy (PVA) Therapeutics and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Postmenopausal Vaginal Atrophy (PVA) Therapeutics revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Postmenopausal Vaginal Atrophy (PVA) Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

Postmenopausal Vaginal Atrophy (PVA) Therapeutics Segment by Company

Teva Pharmaceuticals

Pfizer

Shionogi & Co

Novo Nordisk

Endoceutics

Accord Healthcare

Postmenopausal Vaginal Atrophy (PVA) Therapeutics Segment by Type

Drugs Treatment

Other Treatments

Postmenopausal Vaginal Atrophy (PVA) Therapeutics Segment by Application

Hospital

Clinic

Others

Postmenopausal Vaginal Atrophy (PVA) Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Postmenopausal Vaginal Atrophy (PVA) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Postmenopausal Vaginal Atrophy (PVA) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Postmenopausal Vaginal Atrophy (PVA) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Postmenopausal Vaginal Atrophy (PVA) Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Postmenopausal Vaginal Atrophy (PVA) Therapeutics industry.

Chapter 3: Detailed analysis of Postmenopausal Vaginal Atrophy (PVA) Therapeutics companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Postmenopausal Vaginal Atrophy (PVA) Therapeuticsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Drugs Treatment Table 3. Key Players of Other Treatments Table 4. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Hospital Table 6. Key Players of Clinic Table 7. Key Players of Others Table 8. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 10. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Region (2021-2026) Table 11. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 12. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Region (2027-2032) Table 13. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Trends Table 14. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Drivers Table 15. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Opportunities and Challenges Table 16. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Restraints Table 17. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 18. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Market Share by Company (2021-2026) Table 19. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Key Company Head Office and Area Served Table 21. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Company, Product Type & Application Table 22. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 27. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 28. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Market Share by Type (2021-2026) Table 29. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Market Share by Type (2027-2032) Table 30. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 32. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 33. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Market Share by Application (2021-2026) Table 34. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Market Share by Application (2027-2032) Table 35. Teva Pharmaceuticals Company Information Table 36. Teva Pharmaceuticals Business Overview Table 37. Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio Table 39. Teva Pharmaceuticals Recent Development Table 40. Pfizer Company Information Table 41. Pfizer Business Overview Table 42. Pfizer Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Pfizer Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio Table 44. Pfizer Recent Development Table 45. Shionogi & Co Company Information Table 46. Shionogi & Co Business Overview Table 47. Shionogi & Co Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Shionogi & Co Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio Table 49. Shionogi & Co Recent Development Table 50. Novo Nordisk Company Information Table 51. Novo Nordisk Business Overview Table 52. Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio Table 54. Novo Nordisk Recent Development Table 55. Endoceutics Company Information Table 56. Endoceutics Business Overview Table 57. Endoceutics Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Endoceutics Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio Table 59. Endoceutics Recent Development Table 60. Accord Healthcare Company Information Table 61. Accord Healthcare Business Overview Table 62. Accord Healthcare Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Accord Healthcare Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio Table 64. Accord Healthcare Recent Development Table 65. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 66. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 67. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 68. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 69. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 70. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021-2026) Table 71. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2027-2032) Table 72. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 73. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 74. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 75. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 76. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 77. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021-2026) Table 78. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2027-2032) Table 79. China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 80. China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 81. China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 82. China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 83. Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 84. Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 85. Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 86. Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 87. Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 88. Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021-2026) Table 89. Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2027-2032) Table 90. South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 91. South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 92. South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 93. South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 94. South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021-2026) Table 96. South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2027-2032) Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Image Figure 2. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Type: 2025 VS 2032 Figure 4. Drugs Treatment Image Figure 5. Other Treatments Image Figure 6. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 7. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Application: 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Others Image Figure 11. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 13. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Region: 2025 VS 2032 Figure 14. Years Considered Figure 15. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Players in 2025 Figure 16. Global Top 5 and 10 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Players Market Share by Revenue in 2025 Figure 17. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Market Share by Type (2021-2032) Figure 20. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Market Share by Application (2021-2032) Figure 22. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 23. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Type (2021-2032) Figure 24. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Application (2021-2032) Figure 25. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Country (2021-2032) Figure 26. United States Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 27. Canada Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 28. Mexico Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 29. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 30. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Type (2021-2032) Figure 31. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Application (2021-2032) Figure 32. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Country (2021-2032) Figure 33. Germany Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 34. France Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 35. U.K. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 36. Italy Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 37. Russia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 38. Nordic Countries Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 39. China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 40. China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Type (2021-2032) Figure 41. China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Application (2021-2032) Figure 42. Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 43. Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Type (2021-2032) Figure 44. Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Application (2021-2032) Figure 45. Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Country (2021-2032) Figure 46. Japan Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 47. South Korea Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 48. Taiwan Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 49. Southeast Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 50. India Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 51. Australia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 52. South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Type (2021-2032) Figure 54. South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Application (2021-2032) Figure 55. South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Country (2021-2032) Figure 56. Brazil Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 57. South Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 58. Saudi Arabia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 59. Turkey Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 60. Argentina Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 61. UAE Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 62. Egypt Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 63. Chile Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 64. Research Process Figure 65. Key Executives Interviewed

Scope & coverage.

Types
  • Drugs Treatment
  • Other Treatments
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Teva Pharmaceuticals
  • Pfizer
  • Shionogi & Co
  • Novo Nordisk
  • Endoceutics
  • Accord Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Drugs Treatment
  5. 1.2.3 Other Treatments
  6. 1.3 Market Analysis by Application
  7. 1.3.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.3.4 Others
  11. 1.4 Global Market Growth Prospects
  12. 1.5 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Growth Trends by Region
  13. 1.5.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  14. 1.5.2 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Region (2021-2026)
  15. 1.5.3 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Region (2027-2032)
  16. 1.6 Assumptions and Limitations
  17. 1.7 Study Goals and Objectives
  18. 1.8 Years Considered
2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Dynamics
  1. 2.1 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Trends
  2. 2.2 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Drivers
  3. 2.3 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Company (2021-2026)
  2. 3.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Key Company Head office and Area Served
  4. 3.4 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Company, Product Type & Application
  5. 3.5 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Tier 1, Tier 2, and Tier 3
4 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market by Type
  1. 4.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2021-2032)
  3. 4.3 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Share by Type (2021-2032)
5 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market by Application
  1. 5.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2021-2032)
  3. 5.3 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Teva Pharmaceuticals
  2. 6.1.1 Teva Pharmaceuticals Company Information
  3. 6.1.2 Teva Pharmaceuticals Business Overview
  4. 6.1.3 Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio
  6. 6.1.5 Teva Pharmaceuticals Recent Developments
  7. 6.2 Pfizer
  8. 6.2.1 Pfizer Company Information
  9. 6.2.2 Pfizer Business Overview
  10. 6.2.3 Pfizer Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Pfizer Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio
  12. 6.2.5 Pfizer Recent Developments
  13. 6.3 Shionogi & Co
  14. 6.3.1 Shionogi & Co Company Information
  15. 6.3.2 Shionogi & Co Business Overview
  16. 6.3.3 Shionogi & Co Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Shionogi & Co Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio
  18. 6.3.5 Shionogi & Co Recent Developments
  19. 6.4 Novo Nordisk
  20. 6.4.1 Novo Nordisk Company Information
  21. 6.4.2 Novo Nordisk Business Overview
  22. 6.4.3 Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio
  24. 6.4.5 Novo Nordisk Recent Developments
  25. 6.5 Endoceutics
  26. 6.5.1 Endoceutics Company Information
  27. 6.5.2 Endoceutics Business Overview
  28. 6.5.3 Endoceutics Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Endoceutics Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio
  30. 6.5.5 Endoceutics Recent Developments
  31. 6.6 Accord Healthcare
  32. 6.6.1 Accord Healthcare Company Information
  33. 6.6.2 Accord Healthcare Business Overview
  34. 6.6.3 Accord Healthcare Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Accord Healthcare Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio
  36. 6.6.5 Accord Healthcare Recent Developments
7 North America
  1. 7.1 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032)
  2. 7.2 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type
  3. 7.2.1 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2021-2026)
  4. 7.2.2 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2027-2032)
  5. 7.2.3 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Type (2021-2032)
  6. 7.3 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application
  7. 7.3.1 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2021-2026)
  8. 7.3.2 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2027-2032)
  9. 7.3.3 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Application (2021-2032)
  10. 7.4 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country
  11. 7.4.1 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021-2026)
  13. 7.4.3 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2027-2032)
  14. 7.4.4 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032)
  2. 8.2 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type
  3. 8.2.1 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2021-2026)
  4. 8.2.2 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2027-2032)
  5. 8.2.3 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Type (2021-2032)
  6. 8.3 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application
  7. 8.3.1 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2021-2026)
  8. 8.3.2 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2027-2032)
  9. 8.3.3 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Application (2021-2032)
  10. 8.4 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country
  11. 8.4.1 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021-2026)
  13. 8.4.3 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2027-2032)
  14. 8.4.4 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032)
  2. 9.2 China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type
  3. 9.2.1 China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2021-2026)
  4. 9.2.2 China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2027-2032)
  5. 9.2.3 China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Type (2021-2032)
  6. 9.3 China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application
  7. 9.3.1 China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2021-2026)
  8. 9.3.2 China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2027-2032)
  9. 9.3.3 China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032)
  2. 10.2 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type
  3. 10.2.1 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2021-2026)
  4. 10.2.2 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2027-2032)
  5. 10.2.3 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Type (2021-2032)
  6. 10.3 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application
  7. 10.3.1 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2021-2026)
  8. 10.3.2 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2027-2032)
  9. 10.3.3 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Application (2021-2032)
  10. 10.4 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country
  11. 10.4.1 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021-2026)
  13. 10.4.3 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2027-2032)
  14. 10.4.4 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst